Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) hit a new 52-week high during trading on Saturday . The stock traded as high as $20.00 and last traded at $19.50, with a volume of 39684 shares traded. The stock had previously closed at $17.41.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on TLX shares. William Blair upgraded Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a research report on Tuesday, November 19th. UBS Group upped their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, January 27th.
Check Out Our Latest Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Up 12.0 %
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Recommended Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- Stock Dividend Cuts Happen Are You Ready?
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- What Are Dividend Champions? How to Invest in the Champions
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.